Atlanta + 1.404.581.8401

Swathi Padmanabhan's practice focuses on capital markets, corporate governance, and federal securities law. She has represented public and private companies and underwriters in a wide range of corporate transactions, including initial public offerings, activist defense and proxy contests, public and private debt offerings, restructurings, tender offers, and exchange offers. In addition, Swathi advises clients on corporate governance, shareholder activism, securities laws, stock exchange rules and regulations, and periodic reporting responsibilities.

Swathi also has significant M&A experience and has represented public and private companies and private equity firms in mergers, acquisitions, divestitures, spin-offs, and joint ventures. She has represented clients in a variety of industries, including health care, life sciences, financial institutions, military, real estate, telecommunications, and the public sector.

Swathi has researched and published several articles pertaining to corporate and technology law matters, including first authoring an article on the importance of strategic technology transfer partnerships with respect to the enabling HPV vaccine technologies in Nature Biotechnology, which at the time of publication officials at the World Health Organization recognized as one of the most rigorous technical analyses written on the subject to date. Swathi serves as a member of the Advisory Council of the Atlanta Symphony Orchestra.


  • Helios Technologies acquires Balboa Water Group for $218.5 millionJones Day advised Helios Technologies in the $218.5 million acquisition of BWG Holdings I Corp. (operating as Balboa Water Group) from investment funds affiliated with AEA Investors LP.
  • Sumitomo Dainippon Pharma acquires late stage biopharma companies and forms alliance with Roivant Sciences Ltd. worth $3 billionJones Day advised Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo") in an acquisition of late stage biopharma companies and formation of alliance with Roivant Sciences Ltd.
  • Misonix acquires Solsys Medical, LLC for $109 millionJones Day advised Misonix, Inc. in its acquisition of Solsys Medical, LLC, a privately held regenerative medical company, in an all-stock transaction valued at approximately $109 million.
  • Additional Publications

    Publications Prior to Jones Day


    March 2014
    Tips and Tactics for Transmitting PHI by Email, coauthor, AHLA Connections

    Fall 2012
    Hacking for Lulz: Employing Expert Hackers to Combat Cyber Terrorism, 15 Vand. J. Ent. & Tech. L. 191

    Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India, Nature Biotechnology, Vol. 28

    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.